Biopharma Dealmaking 2024
Access webinar replay
It’s been a difficult year for biopharma dealmaking but there might be light at the end of the tunnel.
With market leading drugs facing LOE events, top pharma companies are ready to forge partnerships with leading biotechs to fill their pipelines. The life science IPO market has been flat for the last few years yet there are signs things could be turning around there, too. Venture capitalists are competing with pharma for early-stage innovators and partnering conference panelists are keen to remind audiences that there is a lot of money out there for strong science. With M&A continuing to hold strong right through December, will it turn even more aggressive in the year ahead?
To kick-off a new year in partnering, Chris Dokomajilar, founder and CEO of DealForma, joins Inpart in this exclusive webinar.
He’ll draw on DealForma’s unrivaled datasets to offer a review of the dealmaking we saw in 2023 as well as make some predictions about the partnering, investment, and M&A landscape that awaits the industry in 2024.
- Why 2024 might be the year that life science IPOs make a comeback
- The therapeutic areas and modalities that are grabbing the spotlight in the post-IRA world
- Where biotechs will turn for funding: public markets, venture capital, or licensing deals?